Compounds > 5-benzylacyclouridine
Page last updated: 2024-12-06

5-benzylacyclouridine

Description

5-Benzylacyclouridine is a synthetic nucleoside analog that has been studied for its potential antiviral and antitumor activities. It is an analog of uridine, a naturally occurring nucleoside, and differs from uridine by the presence of a benzyl group at the 5' position. The benzyl group modification enhances the compound's stability and bioavailability, allowing it to penetrate cells more effectively. 5-Benzylacyclouridine has been shown to inhibit the replication of several viruses, including herpes simplex virus and cytomegalovirus. It is believed to exert its antiviral effect by acting as a substrate for viral DNA polymerases, ultimately leading to the termination of viral DNA synthesis. Moreover, 5-Benzylacyclouridine has also been investigated for its anticancer properties. Studies have indicated that it can inhibit the growth of various cancer cell lines, suggesting its potential as a therapeutic agent for cancer treatment. Further research is ongoing to explore its pharmacological profile and potential applications in the treatment of viral infections and cancer.'

5-benzylacyclouridine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-benzyl-1-(2-hydroxyethoxymethyl)uracil : A pyrimidone that is uracil which is substituted by a 2-hydroxyethoxymethyl group at position 1 and a benzyl group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54929
CHEMBL ID17432
CHEBI ID41037
SCHEMBL ID7558156
MeSH IDM0106894

Synonyms (28)

Synonym
5-benzyl-1-(2-hydroxyethoxymethyl)uracil
5-benzylacyclouridine
82857-69-0
2,4(1h,3h)-pyrimidinedione, 1-[(2-hydroxyethoxy)methyl]-5-(phenylmethyl)-
benzylacyclouridine
5-benzyl-1-(2-hydroxyethoxymethyl)pyrimidine-2,4-dione
1-((2-hydroxyethoxy)methyl)-5-benzylpyrimidine-2,4(1h,3h)-dione
2,4(1h,3h)-pyrimidinedione, 1-((2-hydroxyethoxy)methyl)-5-(phenylmethyl)-
5-benzyl-1-(2'-hydroxyethoxymethyl)uracil
5-bacu
DB07437
CHEMBL17432 ,
chebi:41037 ,
bdbm50026387
5-benzyl-1-(2-hydroxy-ethoxymethyl)-1h-pyrimidine-2,4-dione
0h851i3o9d ,
unii-0h851i3o9d
SCHEMBL7558156
5-benzyl-1-[(2-hydroxyethoxy)methyl]pyrimidine-2,4(1h,3h)-dione
DTXSID30232034
Q27096656
MS-23926
HY-106406
5-benzyl-1-[(2-hydroxyethoxy)methyl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
EN300-6739960
CS-0025738
AKOS040758372
Z3212792438

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" administration followed first-order kinetics with a half-life of approximately 36 min."( Benzylacyclouridine. Pharmacokinetics, metabolism and biochemical effects in mice.
Darnowski, JW; Handschumacher, RE, 1988)		0.27
" In addition, uridine pharmacokinetics were associated with a time-dependent relationship as evidenced by an increased total plasma clearance, renal clearance and volume of distribution, resulting in a substantial decrease in uridine peak concentration with time."( Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
Anderson, DC; Cretton, EM; el Kouni, MH; Kidd, LB; McClure, HM; Sommadossi, JP, 1995)		0.68

Compound-Compound Interactions

ExcerptReferenceRelevance
" Mice receiving the combination of tubercidin (or nebularine) plus NBMPR-P or dilazep, as well as those that survived the combination with dipyridamole, appeared healthy and were found to have normal size livers and spleens."( Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors.
Cha, S; el Kouni, MH; Messier, NJ, 1987)		0.27

Bioavailability

ExcerptReferenceRelevance
" with BAU at 90 mg/kg, and a comparison of the AUC values showed an oral bioavailability of 70%."( Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.
Baccanari, DP; Chandrasurin, P; Davis, ST; Joyner, SS, 1993)		0.52
"6 h in dogs, with bioavailability levels of 85% (30 mg/kg) and 42."( Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
Burtness, BA; Calabresi, P; Chu, E; Chu, MY; Chu, SH; Darnowski, JW; Handschumacher, RE; Leffert, JJ; Marsh, JC; Pizzorno, G; Yee, L, 1998)		0.3

Dosage Studied

ExcerptRelevanceReference
" Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation."( Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Allegra, CJ; Grogan, L; Sotos, GA, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
hydroxyetherAny ether carrying a hydroxy group at unspecified position.
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Uridine phosphorylase 1Mus musculus (house mouse)IC50 (µMol)0.46000.08402.08135.7000AID215632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Uridine phosphorylase 1Homo sapiens (human)Kd2.60000.02001.49956.6000AID1054084; AID1054085; AID1054086; AID1054087
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Uridine phosphorylase 1Homo sapiens (human)Kii0.22350.13000.77102.5460AID1054090; AID1054092
Uridine phosphorylase 1Homo sapiens (human)Kis0.54700.37501.02422.6100AID1054091
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processUridine phosphorylase 1Homo sapiens (human)
uridine catabolic processUridine phosphorylase 1Homo sapiens (human)
CMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dCMP catabolic processUridine phosphorylase 1Homo sapiens (human)
cellular response to glucose starvationUridine phosphorylase 1Homo sapiens (human)
UMP salvageUridine phosphorylase 1Homo sapiens (human)
UMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dTMP catabolic processUridine phosphorylase 1Homo sapiens (human)
dUMP catabolic processUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
uridine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
thymidine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
identical protein bindingUridine phosphorylase 1Homo sapiens (human)
deoxyuridine phosphorylase activityUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
nucleoplasmUridine phosphorylase 1Homo sapiens (human)
cytosolUridine phosphorylase 1Homo sapiens (human)
cytosolUridine phosphorylase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1054087Binding affinity to human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054084Binding affinity to human recombinant UP1-R1P binary complex expressed in Escherichia coli Rosetta (DE3) at 150 uM R1P by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054079Effect on 5-FU-induced cytotoxicity against human HaCaT cells at 30 uM after 72 hrs by MTT assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID215630Tested for inhibition of Uridine Phosphorylase (UrdPase) in murine liver1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Inhibition of uridine phosphorylase. Synthesis and structure-activity relationships of aryl-substituted 1-((2-hydroxyethoxy)methyl)-5-(3-phenoxybenzyl)uracil.
AID1054090Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using inorganic phosphate as substrate assessed as equilibrium dissociation constant for enzyme-substrate-inhibitor complex by Lineweaver-Burk plot analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054085Binding affinity to human recombinant UP1-R1P binary complex expressed in Escherichia coli Rosetta (DE3) at 50 uM R1P by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054078Potentiation of 5-FU-induced cytotoxicity against human HT-29 cells assessed as reduction in compound IC50 at 30 uM after 72 hrs by MTT assay relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054076Inhibition of mouse UPase by Dixon plot analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054092Competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD as substrate by Lineweaver-Burk plot analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID215631Binding affinity was determined against uridine phosphorylase in Sarcoma 180 cells1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis of 1-[[2-hydroxy-1-(hydroxymethyl)ethoxy] methyl]-5-benzyluracil and its amino analogue, new potent uridine phosphorylase inhibitors with high water solubility.
AID1054091Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using inorganic phosphate as substrate assessed as equilibrium dissociation constant for enzyme-inhibitor complex by Lineweaver-Burk plot analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID1054086Binding affinity to human recombinant UP1-inorganic phosphate binary complex expressed in Escherichia coli Rosetta (DE3) by isothermal titration calorimetric analysis2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity.
AID215632Inhibition of uridine phosphorylase (UrdPase) from murine liver.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (45.16)18.7374
1990's14 (45.16)18.2507
2000's1 (3.23)29.6817
2010's2 (6.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.07 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.13%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (90.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phosphonoacetic acid
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.		3.4820monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
dihydrouracil
hexahydropyrimidine-2,4-dione: structure in first source. 5,6-dihydrouracil : A pyrimidine obtained by formal addition of hydrogen across the 5,6-position of uracil.		1.9810pyrimidoneEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		7.61271pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
dilazep
Dilazep: Coronary vasodilator with some antiarrhythmic activity.. dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.		2.3720benzoate ester;
diazepane;
diester;
methoxybenzenes		cardioprotective agent;
platelet aggregation inhibitor;
vasodilator agent
dipyridamole
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.		2.6630piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		4.1850nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
thymidine
[no description available]		1.9710pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		1.9610nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
idoxuridine
[no description available]		3.0810organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		3.4820aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
uridine
[no description available]		5.15150uridinesdrug metabolite;
fundamental metabolite;
human metabolite
cytidine
[no description available]		1.9710cytidinesEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		1.9710antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
toyocamycin
Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.		1.9710antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside		antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
deoxycytidine
[no description available]		1.9710pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		3.7730azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.3720adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
nebularine
nebularine: structure. nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage.		1.9710purine ribonucleoside;
purines D-ribonucleoside		fungal metabolite
2,6-dihydroxypyridine
2,6-dihydroxypyridine: inhibits dihydropyrimidine dehydrogenase		2.0810dihydroxypyridine
3-cyano-6-hydroxy-4-methyl-2-pyridone
3-cyano-6-hydroxy-4-methyl-2-pyridone: structure in first source		2.0810
2,6-dihydroxy-3-cyanopyridine
2,6-dihydroxy-3-cyanopyridine: inhibitor of 5-fluorouracil degradation		2.0810
5-chloro-2'-deoxycytidine
[no description available]		1.9710
nitrobenzylthioinosine 5'-monophosphate
nitrobenzylthioinosine 5'-monophosphate: RN given refers to parent cpd		2.3720
methotrexate
[no description available]		3.0810dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
5-benzyloxybenzylacyclouridine
5-benzyloxybenzylacyclouridine: structure given in first source. 5-benzyloxybenzylacyclouridine : A benzyl ether that consists of acyclouridine bearing a 3-(benzyloxy)benzyl substituent at position 5.		3.0750benzyl ether;
hydroxyether;
primary alcohol
5-benzyluracil
5-benzyluracil: structure in first source		1.9810
9-deazaadenosine
[no description available]		1.9710
5-fluoro-2'-deoxycytidine
5-fluoro-2'-deoxycytidine: structure		1.9710
thioinosine
Thioinosine: Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503)		2.3720
cystine
[no description available]		2.0610
tetrahydrouridine
Tetrahydrouridine: An inhibitor of nucleotide metabolism.		2.3720
levoleucovorin
Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.		3.08105-formyltetrahydrofolic acidantineoplastic agent;
metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Sarcoma 180
An experimental sarcoma of mice.		01.9610
Cancer of Lung
[description not available]		01.9610
Cancer of Pancreas
[description not available]		01.9610
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9610
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		01.9610
Experimental Leukemia
[description not available]		02.3720
Leukemia L5178
An experimental lymphocytic leukemia of mice.		01.9610
Experimental Neoplasms
[description not available]		02.3820
Colorectal Cancer
[description not available]		02.910
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.910
Cancer of Colon
[description not available]		02.6630
Colonic Neoplasms
Tumors or cancer of the COLON.		02.6630
Cancer of Prostate
[description not available]		01.9910
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9910
Benign Neoplasms
[description not available]		03.320
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.320
Leukocytopenia
[description not available]		02.3820
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		02.3820
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		01.9710
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		02.3820
Acquired Immune Deficiency Syndrome
[description not available]		01.9710
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		01.9710
EHS Tumor
[description not available]		01.9710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9710
Experimental Mammary Neoplasms
[description not available]		01.9710
Hypothermia, Accidental
[description not available]		01.9710
Hypothermia
Lower than normal body temperature, especially in warm-blooded animals.		01.9710
Bilharziasis
[description not available]		01.9710
Schistosomiasis
Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.		01.9710
chemdatabank.com